



Patent Docket P1256R3

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Virginia E. Paton et al. Serial No.: 09/209,023 Filed: December 10, 1998 For: TREATMENT WITH ANTI-ErbB2 ANTIBODIES	Group Art Unit: 1642 Examiner: J. Hunt  <small>CERTIFICATE OF MAILING</small> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on July 5, 2000 <i>Ann Savelli</i> Ann Savelli
--	---

# 86A  
100  
8-18-

AMENDMENT UNDER 37 C.F.R. §1.111

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed January 4, 2000, please amend the above referenced patent application as follows:

IN THE SPECIFICATION:

On page 1, line 28, replace "78-182" with --178-182--.  
On page 5, line 5, replace "(3 Suppl 1)" with --(3 Suppl 2)--.  
On page 15, line 27, replace "for" with --to--.  
On page 17, line 14, replace "doxetaxel (Taxotere)" with --docetaxel (TAXOTERE)--.  
On page 46, line 25, replace "tumor" with --disease--.

IN THE CLAIMS:

Please amend the pending claims as follows. Unamended pending claims are included below and identified as "(Reiterated)" for the Examiner's convenience.

1. (Amended) A method for the treatment of a human patient [susceptible to or diagnosed] with a disorder characterized by overexpression of ErbB2

A1  
b  
D1